These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 34978339)
1. The effectiveness of mRNA-1273 vaccine against COVID-19 caused by Delta variant: A systematic review and meta-analysis. Kow CS; Ramachandram DS; Hasan SS J Med Virol; 2022 May; 94(5):2269-2274. PubMed ID: 34978339 [TBL] [Abstract][Full Text] [Related]
2. The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis. Kow CSC; Ramachandram DS; Hasan SS Inflammopharmacology; 2022 Feb; 30(1):149-157. PubMed ID: 35099680 [TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Kow CS; Hasan SS Inflammopharmacology; 2021 Aug; 29(4):1075-1090. PubMed ID: 34241782 [TBL] [Abstract][Full Text] [Related]
4. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999 [TBL] [Abstract][Full Text] [Related]
5. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint. Chen X; Wang W; Chen X; Wu Q; Sun R; Ge S; Zheng N; Lu W; Yang J; Rodewald L; Yu H BMC Med; 2022 Jan; 20(1):36. PubMed ID: 35086547 [TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant. Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006 [TBL] [Abstract][Full Text] [Related]
7. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. Zeng B; Gao L; Zhou Q; Yu K; Sun F BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843 [TBL] [Abstract][Full Text] [Related]
10. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis. Zou Y; Huang D; Jiang Q; Guo Y; Chen C Front Public Health; 2022; 10():940956. PubMed ID: 35910897 [TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 during Delta variant surge: a preliminary assessment from a case-control study in St. Petersburg, Russia. Barchuk A; Bulina A; Cherkashin M; Berezina N; Rakova T; Kuplevatskaya D; Stanevich O; Skougarevskiy D; Okhotin A BMC Public Health; 2022 Sep; 22(1):1803. PubMed ID: 36138385 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021. Sánchez Ruiz MA; Adonias G; Robaglia-Schlupp A; Rapilly F; Chabert M; Ramalli L; Reilhes O; Bruel C; Malfait P; Chaud P Eur Rev Med Pharmacol Sci; 2022 Apr; 26(7):2586-2591. PubMed ID: 35442474 [TBL] [Abstract][Full Text] [Related]
14. Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021. Winkelman TNA; Rai NK; Bodurtha PJ; Chamberlain AM; DeSilva M; Jeruzal J; Johnson SG; Kharbanda A; Klyn N; Mink PJ; Muscoplat M; Waring S; Yu Y; Drawz PE JAMA Netw Open; 2022 Mar; 5(3):e225018. PubMed ID: 35357452 [TBL] [Abstract][Full Text] [Related]
15. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Tartof SY; Slezak JM; Puzniak L; Hong V; Xie F; Ackerson BK; Valluri SR; Jodar L; McLaughlin JM Lancet Respir Med; 2022 Jul; 10(7):689-699. PubMed ID: 35468336 [TBL] [Abstract][Full Text] [Related]
16. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study. Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024 [TBL] [Abstract][Full Text] [Related]
18. Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic. Aoshima M; Ohfuji S Hum Vaccin Immunother; 2022 Dec; 18(7):2147353. PubMed ID: 36459056 [TBL] [Abstract][Full Text] [Related]
19. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study. McKeigue PM; McAllister DA; Hutchinson SJ; Robertson C; Stockton D; Colhoun HM Lancet Respir Med; 2022 Jun; 10(6):566-572. PubMed ID: 35227416 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants. Monge S; Rojas-Benedicto A; Olmedo C; Martín-Merino E; Mazagatos C; Limia A; Sierra MJ; Larrauri A; Hernán MA; Clin Infect Dis; 2023 Feb; 76(3):e367-e374. PubMed ID: 35687580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]